Genocea Biosciences GNCA announced Friday that the Journal of Clinical Oncology has selected the company’s GEN-009 clinical results presentation at the 2019 ASCO Annual Meeting as a top 10 featured abstract in immuno-oncology.
Genocea develops cancer immunotherapies and presenting results at ASCO can be meaningful for investors. The stock traded higher by 60 percent at $7.13 per share Friday morning.
This week's trader obsession with the low-float momentum names is important to note. The micro-cap company has about 8 million shares in its float.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
